Glucovance 500mg/5mg Tablets – Metformin & Glibenclamide Maximum Strength for Type 2 Diabetes

Drug Class: Biguanide + Sulfonylurea Combination Antidiabetic | Form: Oral Tablet | Prescription Status: Prescription Only (Rx)

What Is Glucovance 500mg/5mg?

Glucovance 500mg/5mg is a prescription fixed-dose combination antidiabetic tablet containing Metformin Hydrochloride 500mg and Glibenclamide 5mg — the highest standard strength of Glucovance, prescribed for patients with Type 2 Diabetes whose blood sugar and HbA1c remain above target despite treatment with the intermediate 500mg/2.5mg strength. It contains the same 500mg Metformin as the intermediate strength but double the Glibenclamide — 5mg versus 2.5mg — delivering the maximum standard sulfonylurea stimulation of pancreatic insulin secretion within the Glucovance range alongside full-dose Metformin's insulin-sensitising and hepatic glucose-suppressing activity.

Glibenclamide 5mg is a clinically potent sulfonylurea dose — producing strong and prolonged stimulation of pancreatic beta cell insulin release that lasts 16 to 24 hours per tablet. At this strength, Glucovance delivers the most powerful oral dual-mechanism antidiabetic effect available within this fixed-dose combination — making it appropriate for patients with more advanced beta cell dysfunction and significant insulin secretory deficit that lower Glibenclamide doses cannot adequately address. The correspondingly higher hypoglycaemia risk at this strength makes strict meal timing, consistent blood glucose monitoring, and patient education on hypoglycaemia recognition and management non-negotiable components of safe treatment.

Glucovance 500mg/5mg must always be taken with meals, must be reached by titration from lower strengths, and must never be stopped suddenly without medical guidance.

What Is Glucovance 500mg/5mg Used For?

Glucovance 500mg/5mg is prescribed for:

• Type 2 Diabetes Mellitus (ذیابیطس — شوگر) — maximum standard dual-agent oral antidiabetic control for patients whose blood glucose and HbA1c remain above target on Glucovance 500mg/2.5mg or equivalent separate therapy
• Advanced beta cell dysfunction — patients with progressive type 2 diabetes where the pancreatic beta cells have lost sufficient secretory capacity that only maximum Glibenclamide stimulation can maintain adequate insulin output
• Step-up from Glucovance 500mg/2.5mg — for patients who have tolerated the intermediate strength without problems but have not achieved their glycaemic targets after adequate trial duration
• Replacement of separate Metformin 500mg and Glibenclamide 5mg tablets — consolidating a two-tablet regimen into a single fixed-dose combination for improved adherence and simplified dosing
• Pre-insulin intensification — the final step of oral antidiabetic optimisation before addition of basal insulin becomes necessary in patients with progressive type 2 diabetes

At this maximum strength, the balance between glycaemic efficacy and hypoglycaemia risk is most critical. Close medical supervision, regular HbA1c monitoring, and consistent patient adherence to meal timing are essential.

How Does Glucovance 500mg/5mg Work?

Metformin Hydrochloride 500mg — Full-Dose Insulin Sensitiser and Hepatic Glucose Suppressor: The 500mg Metformin component is identical to that in Glucovance 500mg/2.5mg — providing full-dose biguanide activity that suppresses hepatic gluconeogenesis through AMPK activation, reduces the liver's excessive glucose release into the bloodstream, and improves peripheral tissue sensitivity to insulin — particularly in skeletal muscle where glucose uptake is most impaired in type 2 diabetes. Metformin's contribution to this combination is constant across both the 2.5mg and 5mg Glibenclamide strengths — the clinical difference between the two strengths lies entirely in the escalated sulfonylurea component.

Glibenclamide 5mg — Maximum Standard Pancreatic Insulin Stimulation: At 5mg — the standard maximum single-tablet sulfonylurea dose — Glibenclamide produces its strongest and most sustained stimulation of pancreatic beta cell insulin secretion. By binding with high affinity to SUR1 subunits of ATP-sensitive potassium channels on beta cell membranes, Glibenclamide closes these channels and triggers the full sequence of membrane depolarisation, voltage-gated calcium channel opening, calcium influx, and insulin granule exocytosis — releasing the maximum pharmacologically stimulated insulin output the beta cells can generate. This potent and prolonged insulin secretion — sustained for 16 to 24 hours — addresses the most significant beta cell secretory deficits seen in more advanced type 2 diabetes where lower sulfonylurea doses are no longer sufficient to maintain postprandial and fasting glucose control.

Why the Maximum Glibenclamide Dose Carries the Highest Hypoglycaemia Risk: At 5mg Glibenclamide, insulin secretion is stimulated at its maximum pharmacological level — independent of the prevailing blood glucose concentration. If a meal is skipped, delayed, or insufficient in carbohydrate content, the insulin released by 5mg Glibenclamide drives blood glucose to fall without the corresponding food-driven glucose rise to balance it — producing hypoglycaemia that can be severe and prolonged. The 16 to 24-hour duration of Glibenclamide's action at this dose means that hypoglycaemia occurring hours after the tablet is taken is still driven by residual drug activity — making recurrence after initial treatment a significant clinical concern requiring sustained monitoring and often hospital observation.

The Complete Dual-Mechanism Effect: At the 500mg/5mg strength, both components operate at their full respective doses — Metformin providing maximum insulin-sensitising and hepatic glucose-suppressing activity, and Glibenclamide providing maximum pancreatic insulin secretion stimulation. The two mechanisms remain complementary and non-overlapping — together addressing all three core pathophysiological defects of type 2 diabetes more completely than any oral single-agent therapy. For patients who do not achieve targets at this strength, the next clinical step is typically addition of basal insulin to the existing oral regimen rather than further dose escalation.

Dosage and Administration

⚠️ This is the maximum standard Glucovance strength — never exceed two tablets twice daily without specialist instruction. Always take with meals — skipping a meal after taking this tablet is a direct and serious hypoglycaemia risk at the 5mg Glibenclamide dose. Carry fast-acting glucose at all times. Monitor blood glucose regularly. Stop before any surgery, CT scan with contrast, or fasting procedure and restart only after medical clearance.

Titration Pathway to This Strength: Glucovance 500mg/5mg should only be reached after adequate trial of lower strengths — 250mg/1.25mg as initiation, then 500mg/2.5mg as intermediate step. Jumping directly to the 500mg/5mg strength without titration through lower doses significantly increases hypoglycaemia risk and is not recommended except when replacing a previously established equivalent separate-tablet regimen under medical supervision.

Meal Timing — Maximum Importance at This Strength:

• Take with the first bite of breakfast for the morning dose and with the first bite of the evening meal for the second dose
• If a meal must be skipped for any reason — skip the corresponding Glucovance dose entirely
• Never take this tablet and then delay eating by more than 15 to 20 minutes
• Physical activity planned after a dose requires extra carbohydrate intake or dose adjustment — discuss with your doctor

How to Take:

1. Swallow the tablet whole with a full glass of water
2. Take at the start of a meal — never before or separately from food
3. Maintain consistent mealtimes every day for predictable blood glucose control
4. If a dose is missed and the meal has passed — skip; never double up at the next meal
5. Do not crush or split tablets unless specifically advised

Active Ingredients

Who Should NOT Take Glucovance 500mg/5mg?

Do not take Glucovance 500mg/5mg if you:

• Have Type 1 Diabetes — not indicated
• Have diabetic ketoacidosis — requires immediate insulin treatment
• Have significant kidney impairment — Metformin lactic acidosis risk; Glibenclamide accumulation also increases hypoglycaemia duration; eGFR must be assessed
• Have severe liver disease — both components contraindicated in significant hepatic impairment
• Have G6PD deficiency — sulfonylureas cause haemolytic anaemia
• Are scheduled for surgery under general anaesthesia — stop 48 hours before; restart only after kidney function confirmed normal
• Are having a CT scan or angiogram with contrast dye — withhold 48 hours before and after
• Have severe heart failure, respiratory failure, or recent heart attack — tissue hypoxia increases Metformin lactic acidosis risk
• Are allergic to Metformin, Glibenclamide, other sulfonylureas, or any ingredient
• Consume excessive alcohol
• Are elderly with significant comorbidities — hypoglycaemia risk at 5mg Glibenclamide is particularly dangerous in frail elderly patients

Always consult your doctor before use if you:

• Have any degree of kidney impairment — both components require dose adjustment and closer monitoring
• Are elderly — use at this maximum strength requires careful specialist assessment; lower strengths are strongly preferred
• Are pregnant — insulin is standard of care; specialist assessment required
• Are breastfeeding — Glibenclamide passes into breast milk
• Have irregular meal patterns — maximum-dose Glibenclamide and unpredictable meal timing is a dangerous combination

Side Effects

Common:

• Hypoglycaemia (شوگر کا گرنا) — highest risk among all three Glucovance strengths; sweating, trembling, dizziness, palpitations, confusion, weakness, blurred vision — always carry fast-acting glucose; risk is substantially elevated if meals are skipped, alcohol consumed, or physical activity increased without dose adjustment
• Nausea, stomach discomfort, or diarrhoea — Metformin-related; reduced by taking with food
• Metallic taste — Metformin effect; fades with continued use
• Weight gain — Glibenclamide-driven insulin secretion is most pronounced at 5mg; dietary management is essential
• Mild skin rash or itching — sulfonylurea-related

Serious — Seek Emergency Medical Attention Immediately:

• Severe hypoglycaemia — loss of consciousness, seizures, or inability to swallow — administer glucagon injection if available; call emergency services immediately; at 5mg Glibenclamide, hypoglycaemia can persist and recur for 24 hours or more — hospital observation and intravenous glucose infusion are often required for severe episodes (یہ طبی ہنگامی صورتحال ہے)
• Lactic acidosis — rare but life-threatening Metformin complication; severe muscle pain, difficulty breathing, abdominal pain, feeling cold, irregular heartbeat — emergency medical care required immediately (یہ طبی ہنگامی صورتحال ہے)
• Severe allergic reaction — rash, swelling of face, lips, or throat, difficulty breathing (یہ طبی ہنگامی صورتحال ہے)
• Haemolytic anaemia — rare in G6PD-deficient patients; pallor, jaundice, dark urine
• Liver effects — jaundice, dark urine, severe fatigue — rare with Glibenclamide

Drug Interactions

Storage Instructions

• Store below 25°C in a cool, dry place
• Protect from moisture and direct sunlight
• Keep in original blister pack until use
• Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
• Do not use after the expiry date on the pack or carton

Frequently Asked Questions

What makes Glucovance 500mg/5mg different from the 500mg/2.5mg strength — when is this maximum dose needed?

Both strengths contain the same 500mg Metformin — the difference is the Glibenclamide dose: 5mg versus 2.5mg. The 500mg/5mg strength is prescribed when patients have been adequately trialled on 500mg/2.5mg for 4 to 8 weeks and their blood glucose and HbA1c still remain above their individual target. This typically reflects more advanced beta cell dysfunction — where the pancreas can no longer produce enough insulin even with 2.5mg Glibenclamide stimulation — requiring the stronger 5mg signal to drive adequate insulin secretion. The important clinical trade-off at this maximum strength is the significantly higher hypoglycaemia risk from the doubled Glibenclamide dose, which makes consistent meal timing and blood glucose monitoring more critical than at any lower Glucovance strength.

If my blood sugar is still not controlled on Glucovance 500mg/5mg — what comes next?

Glucovance 500mg/5mg represents the maximum standard oral dual-agent antidiabetic combination within the Glucovance range. If blood sugar targets are not achieved at this strength despite good adherence, consistent meal timing, and appropriate diet and exercise, the most common next step in type 2 diabetes management is addition of basal insulin — typically a long-acting insulin such as Insulin Glargine or Insulin Detemir administered once daily at bedtime — to the existing oral antidiabetic regimen. This combination of oral antidiabetics plus basal insulin addresses the overnight hepatic glucose production that oral agents alone cannot fully suppress in more advanced type 2 diabetes. Your doctor or endocrinologist will guide this transition based on your HbA1c trajectory, blood glucose pattern, and individual clinical circumstances.

Why is hypoglycaemia from Glucovance 500mg/5mg potentially more dangerous than from lower strengths?

The severity and duration of hypoglycaemia from Glibenclamide are directly related to the dose. At 5mg — the maximum standard dose — Glibenclamide stimulates the strongest and most sustained pancreatic insulin release, with a duration of action reaching 16 to 24 hours. When hypoglycaemia occurs at this dose, the residual Glibenclamide activity continues driving insulin secretion even after the initial low blood sugar is treated with glucose — meaning blood sugar falls again repeatedly unless sustained glucose is provided. This recurrent nature of Glibenclamide-induced hypoglycaemia at higher doses is why a single glucose tablet is never sufficient treatment for severe episodes and why hospital observation with intravenous glucose infusion is often necessary for severe hypoglycaemia from this strength. Immediate emergency medical attention is mandatory for any hypoglycaemic episode involving confusion, inability to swallow, or loss of consciousness while on Glucovance 500mg/5mg.

Is Glucovance 500mg/5mg appropriate for elderly patients?

At this maximum strength, Glucovance 500mg/5mg requires very careful consideration before prescribing in elderly patients. Older patients have several characteristics that make them particularly vulnerable to severe and prolonged hypoglycaemia from 5mg Glibenclamide — reduced hypoglycaemia symptom awareness meaning low blood sugar is not felt until it is already severe, irregular meal patterns, declining kidney function that slows Glibenclamide clearance prolonging its action beyond 24 hours, and the use of multiple interacting medicines. For most elderly patients with type 2 diabetes, lower Glucovance strengths or alternative antidiabetic regimens with lower hypoglycaemia risk — such as DPP-4 inhibitors or SGLT-2 inhibitors added to Metformin — are more appropriate. If this strength is prescribed for an elderly patient, very frequent blood glucose monitoring, strict meal discipline, caregiver awareness of hypoglycaemia management, and regular kidney function checks are all essential.

Can I take Glucovance 500mg/5mg during Ramadan fasting?

Ramadan fasting presents a significant management challenge for patients on Glucovance 500mg/5mg. The normal meal pattern is completely disrupted — with one or two large meals at Sehri and Iftar replacing three regular meals — and the prolonged daytime fast creates a sustained period during which the Glibenclamide component continues stimulating insulin secretion without carbohydrate intake to balance it. This creates a very high risk of severe hypoglycaemia during fasting hours. Patients on Glucovance 500mg/5mg must consult their doctor well before Ramadan begins to plan a medication adjustment strategy — which may include switching to a lower Glucovance strength, changing the dosing schedule, switching to a lower hypoglycaemia-risk antidiabetic regimen for the fasting period, or in some cases being medically advised against fasting. Never self-adjust your antidiabetic regimen during Ramadan without explicit medical guidance.

---

⚕️ Medical Disclaimer: This product description is for general informational purposes only and does not replace professional medical advice. Glucovance 500mg/5mg is the maximum standard strength prescription combination antidiabetic — always use under the supervision of a qualified doctor or endocrinologist. Always take with food. Never skip meals after taking this medicine. Carry fast-acting glucose at all times. Severe hypoglycaemia at this dose is a medical emergency requiring immediate hospital attention. Stop before contrast procedures and surgery — restart only after medical clearance.

Prescription Required (Rx) | Maximum Standard Glucovance Strength | Always Take With Meals — Never Skip | Carry Fast-Acting Glucose at All Times | Severe Hypoglycaemia Requires Emergency Hospital Care | Stop Before Contrast Procedures & Surgery